Placebo pMDI

DRUG5 trials

Sponsors

Chiesi Farmaceutici S.p.A., Verona Pharma Inc

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseCoronavirus InfectionCovid-19SARS-CoV-2

Phase 1

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

CompletedNCT02359292

Chiesi Farmaceutici S.p.A.Asthma

Start: 2015-02-28End: 2015-07-31Updated: 2021-07-02

Phase 2

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

CompletedNCT03084718

Chiesi Farmaceutici S.p.A.Asthma

Start: 2017-07-28End: 2018-12-05Updated: 2021-12-14

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

CompletedNCT03086460

Chiesi Farmaceutici S.p.A.Asthma

Start: 2017-09-08End: 2018-07-28Updated: 2021-08-16

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03590379

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2018-06-15End: 2019-03-06Updated: 2021-04-12

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

CompletedNCT04527471

Verona Pharma IncCoronavirus Infection, Covid-19, SARS-CoV-2

Start: 2020-09-04End: 2021-05-01Updated: 2022-09-22

Related Papers

Efficacy and safety of inhaled extrafine beclomethasone dipropionate in adults with asthma: a randomized, parallel-group, dose-ranging study (BEAM)

Journal of Asthma2021-05-242 citations

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.

2021-01-1416 citations